Cardiol Therapeutics Inc. Email Format

Biotechnology ResearchOntario, Canada11-50 Employees

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company located in Toronto, Ontario, Canada, operating with a workforce of 11-50 employees at 2265 Upper Middle Road East, Suite 602. The company’s research and development targets heart disease, pursuing anti-inflammatory and anti-fibrotic approaches to address inflammation and fibrosis in conditions such as myocarditis, pericarditis, and heart failure. CardiolRx, its lead drug candidate, is a pharmaceutically manufactured cannabidiol oral solution in clinical development for heart disease, with a mechanism tied to inhibition of inflammasome pathways. The US FDA has granted Investigational New Drug authorization to test CardiolRx in recurrent pericarditis and acute myocarditis, including the MAVERIC program (Phase II MAVERIC-Pilot and Phase III MAVERIC) and the ARCHER Phase II trial; the agency has also designated CardiolRx for orphan drug status in pericarditis. Cardiol is also developing CRD-38, a subcutaneously administered treatment candidate aimed at treating heart failure. The company trades on NASDAQ and TSX under the ticker CRDL.

Sign up for free to view info

Company overview Employee directory